Free Trial
LON:EVG

Evgen Pharma (EVG) Share Price, News & Analysis

Evgen Pharma logo
GBX 0.80 0.00 (0.00%)
(As of 04/25/2024)

About Evgen Pharma Stock (LON:EVG)

Key Stats

Today's Range
0.80
0.80
50-Day Range
0.80
0.80
52-Week Range
0.70
4.05
Volume
227,410 shs
Average Volume
1.73 million shs
Market Capitalization
£3.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Receive EVG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evgen Pharma and its competitors with MarketBeat's FREE daily newsletter.

EVG Stock News Headlines

TheraCryf Reports Positive SFX-01 Study Results
Passing of Dr Sue Foden, Chair
Let’s be blunt
Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!
See More Headlines

EVG Stock Analysis - Frequently Asked Questions

Evgen Pharma's stock was trading at GBX 1.60 at the start of the year. Since then, EVG shares have decreased by 50.0% and is now trading at GBX 0.80.
View the best growth stocks for 2024 here
.

Evgen Pharma plc (LON:EVG) issued its quarterly earnings results on Monday, June, 15th. The company reported ($2.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($2.10).

Shares of EVG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evgen Pharma investors own include genedrive (GDR), MOTIF BIO PLC/S (MTFB), B&M European Value Retail (BME), Capital & Counties Properties PLC (CAPC), Coats Group (COA), 4D pharma (DDDD) and Greencore Group (GNC).

Company Calendar

Last Earnings
6/15/2020
Today
11/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Financial Services
CIK
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Net Income
£-3,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 0.47 per share
Book Value
GBX 1 per share

Miscellaneous

Free Float
N/A
Market Cap
£3.42 million
Optionable
Not Optionable
Beta
1.44
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (LON:EVG) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners